Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kunxian Capsule versus mycophenolate mofetil for partially relieved lupus nephritis
ChiCTR1800017190Phase 4Recruiting
- Sponsor
- Department of Rheumatology, Guangdong Provincial Hospital of Chinese Medicine
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Kunxian Capsule in lupus nephritis (LN) (2 arms), sponsored by Department of Rheumatology, Guangdong Provincial Hospital of Chinese Medicine. Primary endpoint: 24-hour urine protein quantification at Week 24. Started May 2018; status: recruiting.
02
Drugs
Kunxian Capsule
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR1800017190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017190.